| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 12/13/2001 | WO2001094401A1 A new polypeptide-human npat protein 15 and the polynucleotide encoding it |
| 12/13/2001 | WO2001094400A2 A GENE ENCODING A MULTIDRUG RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7p15-21 AND USES THEREOF |
| 12/13/2001 | WO2001094399A1 A novel polypeptide - homo synaptosome - associated protein 11.66 and polynucleotide encoding said polypeptide |
| 12/13/2001 | WO2001094397A1 A novel polypeptide-zinc finger protein 79.46 and the polynucleotide encoding said polypeptide |
| 12/13/2001 | WO2001094395A1 A novel polypeptide, a human zinc finger protein 38 and the polynucleotide encoding the polypeptide |
| 12/13/2001 | WO2001094392A2 Recombinant subunit proteins from porcine parvovirus produced in plants |
| 12/13/2001 | WO2001094391A2 Intracellular signaling proteins |
| 12/13/2001 | WO2001094388A2 Zcys6: a member of the cystatin superfamily |
| 12/13/2001 | WO2001094387A2 Epididymis-specific proteins with fibronectin type ii modules |
| 12/13/2001 | WO2001094386A2 Method for the extraction and the use of antibiotically effective peptides for treating infectious diseases |
| 12/13/2001 | WO2001094383A2 Mutated furin polypeptides having improved characteristics |
| 12/13/2001 | WO2001094382A1 Oligopeptides |
| 12/13/2001 | WO2001094381A2 Novel compounds of the n-acylamino-amide family, compositions comprising same, and uses |
| 12/13/2001 | WO2001094374A1 A novel peptide-human adhesion plaque kinase 23.43 and the polynucleotide coding this novel peptide |
| 12/13/2001 | WO2001094293A2 Benzamide ligands for the thyroid receptor |
| 12/13/2001 | WO2001093983A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 12/13/2001 | WO2001093914A2 Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| 12/13/2001 | WO2001093913A2 T cell receptor fusions and conjugates and methods of use thereof |
| 12/13/2001 | WO2001093911A2 Macromolecular drug complexes and compositions containing the same |
| 12/13/2001 | WO2001093905A1 Immunostimulatory oligodeoxynucleotides |
| 12/13/2001 | WO2001093903A1 Antigenic composition comprising a polycationic peptide and inosine and cytosine |
| 12/13/2001 | WO2001093901A1 Combined preparation for the treatment of neoplasic diseases |
| 12/13/2001 | WO2001093900A1 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| 12/13/2001 | WO2001093898A1 Methods of treating viral diseases with il-18 and il-18 combinations |
| 12/13/2001 | WO2001093897A2 Angiostatin and endostatin binding proteins and methods of use |
| 12/13/2001 | WO2001093896A2 A method of treatment of alzheimer's disease with a protein extractable from mammalian organs |
| 12/13/2001 | WO2001093895A2 A method of treatment of huntington's chorea with a protein extractable from mammalian organs |
| 12/13/2001 | WO2001093894A2 A method of treatment of parkinson's disease with a protein extractable from mammalian organs |
| 12/13/2001 | WO2001093893A2 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
| 12/13/2001 | WO2001093890A2 Botulinum toxin implant |
| 12/13/2001 | WO2001093889A2 Vip-related peptides for the treatment of skin disorders |
| 12/13/2001 | WO2001093888A2 A method of treatment of amyotrophic lateral sclerosis with a protein extractable from mammalian organs |
| 12/13/2001 | WO2001093887A1 Skin treatment preparation |
| 12/13/2001 | WO2001093875A1 Compositions for treating biofilm |
| 12/13/2001 | WO2001093861A1 Tissue specific prodrug |
| 12/13/2001 | WO2001093851A2 Compositions and methods for treating neoplastic disease using inhibitors of laminin5beta3 |
| 12/13/2001 | WO2001093847A2 Compositions, kits, and methods for promoting defined health benefits |
| 12/13/2001 | WO2001093837A2 Protein powder for pulmonary delivery |
| 12/13/2001 | WO2001093835A1 Delivery systems for bioactive agents |
| 12/13/2001 | WO2001093833A2 Kits and methods for optimizing the efficacy of chondroprotective compositions |
| 12/13/2001 | WO2001093831A2 Low carbohydrate compositions, kits thereof, and methods of use |
| 12/13/2001 | WO2001093828A1 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| 12/13/2001 | WO2001093827A2 Neurotoxin implant |
| 12/13/2001 | WO2001093806A2 HMG CoA REDUCTASE INHIBITORS FOR PROMOTING ANGIOGENESIS |
| 12/13/2001 | WO2001093804A2 Hepatitis c virus conjugates |
| 12/13/2001 | WO2001093681A1 Modulating angiogenesis and neurogenesis with goliath proteins |
| 12/13/2001 | WO2001070968A3 Production of recombinant blood clotting factors in human cell lines |
| 12/13/2001 | WO2001068675A3 Treatment of rosacea |
| 12/13/2001 | WO2001055325A8 Nucleic acids, proteins, and antibodies |
| 12/13/2001 | WO2001055206A8 Nucleic acids, proteins, and antibodies |
| 12/13/2001 | WO2001055205A8 Nucleic acids, proteins, and antibodies |
| 12/13/2001 | WO2001053335A3 Peptides with antibacterial activity |
| 12/13/2001 | WO2001049275A3 Methods and compositions for mitigating pain using nitrate esters |
| 12/13/2001 | WO2001044445A3 Human lyases and associated proteins |
| 12/13/2001 | WO2001043694A3 Compositions and methods for caspase-induced apoptosis |
| 12/13/2001 | WO2001042262A3 Antithrombotic compound |
| 12/13/2001 | WO2001040475A3 Heme proteins hemat-hs and hemat-bs and their use in medicine and microsensors |
| 12/13/2001 | WO2001040269A3 Compositions and methods for therapy and diagnosis of breast cancer |
| 12/13/2001 | WO2001040264A3 Peptide antigens |
| 12/13/2001 | WO2001039791A3 Tyrosine- and tryptophan-containing peptides as antioxidants |
| 12/13/2001 | WO2001035899A3 Inhibitors of helicobacter pylori induced gastrointestinal diseases |
| 12/13/2001 | WO2001034171A3 Peptides for treatment of erectile dysfunction |
| 12/13/2001 | WO2001030987A3 Tankyrase h, compositions involved in the cell cycle and methods of use |
| 12/13/2001 | WO2001028577A3 Inhibition of cell motility and angiogenesis by inhibitors of the grb2 sh2-domain |
| 12/13/2001 | WO2001027136A3 Peptides which stimulate the immune response and tissue regeneration |
| 12/13/2001 | WO2001026682A3 Modified plant viruses and methods of use thereof |
| 12/13/2001 | WO2001020026A3 POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS |
| 12/13/2001 | WO2001019399A3 Method of potentiating chemotherapy and treating solid tumors |
| 12/13/2001 | WO2001015722A3 Methods useful in affecting apoptosis |
| 12/13/2001 | WO2001011048A3 Therapeutic polypeptides and methods for using same |
| 12/13/2001 | WO2001011038A3 Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds |
| 12/13/2001 | WO2000044888A3 Dimethylarginine dimethylaminohydrolases |
| 12/13/2001 | WO2000033857A9 Cancer treatment composition and method using natural plant essential oils |
| 12/13/2001 | WO2000030656A9 Neuron stimulation by ribavirin, and analogs thereof |
| 12/13/2001 | WO2000029009A9 Peptides having anti-cancer and anti-inflammatory activity |
| 12/13/2001 | WO2000029008A9 Hiv-specific t-cell induction |
| 12/13/2001 | WO2000026340A3 Novel nucleic acid molecules encoding opioid growth factor receptors |
| 12/13/2001 | WO2000018903A9 Inducible genetic suppression of cellular excitability |
| 12/13/2001 | US20010052137 Axin domain-like polypeptide inhibitors of glycogen synthase kinase 3 beta activity and activators of wnt signaling |
| 12/13/2001 | US20010051799 Tissue volume reduction |
| 12/13/2001 | US20010051709 Preferential immunogenic fusion protein; for use in the treatment of autoimmune disorders |
| 12/13/2001 | US20010051660 Method for reducing oxalate |
| 12/13/2001 | US20010051646 Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| 12/13/2001 | US20010051609 Administering Dna |
| 12/13/2001 | US20010051605 Epidermal growth factor inhibitor |
| 12/13/2001 | US20010051604 Mixture containing stabilizers, sodium chloride, buffer and surfactants |
| 12/13/2001 | US20010051603 Dried blood factor composition comprising trehalose |
| 12/13/2001 | US20010051601 Use of growth hormone in low dose |
| 12/13/2001 | US20010051600 Use of interleukin-11 to prevent immune-mediated cytotoxicity |
| 12/13/2001 | US20010051595 Injection into blood |
| 12/13/2001 | US20010051370 Glycosyl sulfotransferase-3 |
| 12/13/2001 | US20010051360 Preferential peptide; for use in the treatment of kinase defects; for treatment of cancer |
| 12/13/2001 | US20010051358 Nucleotide sequences coding preferential pollypeptides; for use in the treatment of nervous system, vision, kidney and liver disorders; wound healing agents; anticarcinogenic agents |
| 12/13/2001 | US20010051191 Bioflavonoid (quercetin) mixed with protelytic digestive enzyme protease (bromelin and papain), also containing cranberry; for treatment of urinary tract infections |
| 12/13/2001 | US20010051157 Therapeutic/cosmetic formulation for therapeutical treatment or care of sensitive human skin, hair, mucous membrane, nails and/or the scalp comprises a calcitonin gene related peptide (CGRP) antagonist and a carrier, diluent or vehicle |
| 12/13/2001 | US20010051154 Mixing with polysaccharide and amino acid |
| 12/13/2001 | US20010051146 Agent for preventing and/or treating multiple organ failure |
| 12/13/2001 | DE10027777A1 Introducing substances into cells of sensory organs, useful for treating degenerative disorders of ear and eye, uses penetratin as transporter molecule |
| 12/13/2001 | DE10027170A1 Humanes PEM als Target für die Fertilitätskontrolle Human PEM as a target for fertility control |
| 12/13/2001 | DE10026998A1 Verfahren zur Herstellung einer kosmetischen Zusammensetzung, die humanes Serum Albumin umfasst, welches aus transgenen nicht-menschlichen Säugern erhalten wurde A process for the preparation of a cosmetic composition comprising human serum albumin, which has been obtained from transgenic non-human mammals |